NCT02175485View on ClinicalTrials.gov

Evaluation of Efficacy of Dellegra in Exposure Unit

PHASE4CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Rhinitis Allergic

Interventions

DRUG

Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg

Pharmaceutical form:tablet Route of administration: oral

Trial Locations (1)

Unknown

Investigational Site Number 392-001, Shinjuku-ku

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT02175485 - Evaluation of Efficacy of Dellegra in Exposure Unit | Biotech Hunter | Biotech Hunter